Aktieanalys

Camurus Q1 2025: Buvidal On Target, Brixadi Flat - Redeye

{newsItem.title}

Redeye Publicerad: 22 May 07:26

Redeye comments on Camurus’ first quarter report 2025, which saw Buvidal sales on track, but Brixadi sales were flat Q/Q on a constant FX basis. We believe the slack in growth is temporary, but we reduce the projected near- and medium-term sales of Brixadi slightly.

Länk till analysen i sin helhet: https://www.redeye.se/research/1110820/camurus-q1-2025-buvidal-on-target-brixadi-flat?utm_source=finwire&utm_medium=RSS

Nyheter om Camurus

Läses av andra just nu

Om aktien Camurus

Senaste nytt